375 related articles for article (PubMed ID: 10617687)
1. Use of constitutive G protein-coupled receptor activity for drug discovery.
Chen G; Way J; Armour S; Watson C; Queen K; Jayawickreme CK; Chen WJ; Kenakin T
Mol Pharmacol; 2000 Jan; 57(1):125-34. PubMed ID: 10617687
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.
Seifert R; Wenzel-Seifert K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):381-416. PubMed ID: 12382069
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors.
Mody SM; Ho MK; Joshi SA; Wong YH
Mol Pharmacol; 2000 Jan; 57(1):13-23. PubMed ID: 10617674
[TBL] [Abstract][Full Text] [Related]
4. Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors.
Bodenstein J; Venter DP; Brink CB
J Pharmacol Exp Ther; 2005 Aug; 314(2):891-905. PubMed ID: 15857948
[TBL] [Abstract][Full Text] [Related]
5. Gi-mediated translocation of GLUT4 is independent of p85/p110alpha and p110gamma phosphoinositide 3-kinases but might involve the activation of Akt kinase.
Wang L; Hayashi H; Kishi K; Huang L; Hagi A; Tamaoka K; Hawkins PT; Ebina Y
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):543-55. PubMed ID: 10642513
[TBL] [Abstract][Full Text] [Related]
6. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
Westphal RS; Sanders-Bush E
Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
[TBL] [Abstract][Full Text] [Related]
7. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
8. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
Pauwels PJ; Tardif S; Wurch T; Colpaert FC
J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction.
Heydorn A; Ward RJ; Jorgensen R; Rosenkilde MM; Frimurer TM; Milligan G; Kostenis E
Mol Pharmacol; 2004 Aug; 66(2):250-9. PubMed ID: 15266015
[TBL] [Abstract][Full Text] [Related]
10. Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.
Leuthäuser K; Gujer R; Aldecoa A; McKinney RA; Muff R; Fischer JA; Born W
Biochem J; 2000 Oct; 351 Pt 2(Pt 2):347-51. PubMed ID: 11023820
[TBL] [Abstract][Full Text] [Related]
11. Constitutive receptor systems for drug discovery.
Chen G; Jayawickreme C; Way J; Armour S; Queen K; Watson C; Ignar D; Chen WJ; Kenakin T
J Pharmacol Toxicol Methods; 1999 Dec; 42(4):199-206. PubMed ID: 11033435
[TBL] [Abstract][Full Text] [Related]
12. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.
Seifert R; Wenzel-Seifert K; Gether U; Kobilka BK
J Pharmacol Exp Ther; 2001 Jun; 297(3):1218-26. PubMed ID: 11356949
[TBL] [Abstract][Full Text] [Related]
13. An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.
Mistry R; Dowling MR; Challiss RA
Br J Pharmacol; 2005 Feb; 144(4):566-75. PubMed ID: 15655507
[TBL] [Abstract][Full Text] [Related]
14. Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay.
Fitzgerald LR; Mannan IJ; Dytko GM; Wu HL; Nambi P
Anal Biochem; 1999 Nov; 275(1):54-61. PubMed ID: 10542109
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor.
Ma JN; Currier EA; Essex A; Feddock M; Spalding TA; Nash NR; Brann MR; Burstein ES
Biochem Pharmacol; 2004 Apr; 67(7):1279-84. PubMed ID: 15013843
[TBL] [Abstract][Full Text] [Related]
16. G(alpha)s levels regulate Xenopus laevis oocyte maturation.
Romo X; Hinrichs MV; Guzmán L; Olate J
Mol Reprod Dev; 2002 Sep; 63(1):104-9. PubMed ID: 12211067
[TBL] [Abstract][Full Text] [Related]
17. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.
Lane JR; Powney B; Wise A; Rees S; Milligan G
J Pharmacol Exp Ther; 2008 Apr; 325(1):319-30. PubMed ID: 18218829
[TBL] [Abstract][Full Text] [Related]
18. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis.
Ganguli SC; Park CG; Holtmann MH; Hadac EM; Kenakin TP; Miller LJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):593-8. PubMed ID: 9694908
[TBL] [Abstract][Full Text] [Related]
19. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors.
Dong M; Pinon DI; Asmann YW; Miller LJ
Mol Pharmacol; 2006 Jul; 70(1):206-13. PubMed ID: 16531505
[TBL] [Abstract][Full Text] [Related]
20. Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.
Ramsay D; Bevan N; Rees S; Milligan G
Br J Pharmacol; 2001 May; 133(2):315-23. PubMed ID: 11350868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
